---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-26-000011"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2026-02-06T23:59:59+00:00"
generated_at: "2026-05-16T04:13:39.472464+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biogen Q4 revenue $2.3B, GAAP EPS loss $(0.33); FY2025 Non-GAAP EPS $15.28 beats guidance

## Summary
- Q4 total revenue $2.3B (-7% YoY); GAAP diluted EPS $(0.33); Non-GAAP diluted EPS $1.99.
- Full year total revenue $9.9B (+2% YoY); GAAP diluted EPS $8.79; Non-GAAP EPS $15.28 above $14.50-$15.00 guidance.
- Growth products up 6% YoY in Q4; LEQEMBI global in-market sales $134M (+54% YoY).
- FY2026 guidance: Non-GAAP diluted EPS $15.25-$16.25; total revenue to decline mid-single digit percent vs FY2025.
- Pipeline: LEQEMBI subcutaneous PDUFA May 24, 2026; litifilimab Breakthrough Therapy for CLE; high-dose SPINRAZA PDUFA Apr 3.

## SEC filing metadata
- accession: 0000875045-26-000011
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2026-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504526000011/0000875045-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504526000011/biib-20260206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-26-000011
- JSON: https://secwatch.observer/filing/0000875045-26-000011.json
- Plain text: https://secwatch.observer/filing/0000875045-26-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.